Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Has Consensus Price Target of $8.75 According to Analysts

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been assigned an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $8.75.

Several research firms recently commented on PYXS. HC Wainwright boosted their price objective on shares of Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Wells Fargo & Company increased their target price on Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pyxis Oncology in a report on Friday, September 25th. Wedbush lifted their target price on Pyxis Oncology from $6.00 to $8.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Finally, Leerink Partners lowered their price target on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, July 2nd.

Pyxis Oncology Stock Performance

Shares of PYXS stock opened at $2.03 on Friday. The company has a market capitalization of $169.32 million, a P/E ratio of -1.44 and a beta of 1.37. The company’s 50 day moving average price is $3.10 and its two-hundred day moving average price is $2.41. Pyxis Oncology has a 52 week low of $1.03 and a 52 week high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Analysts forecast that Pyxis Oncology will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC grew its stake in Pyxis Oncology by 22.0% in the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after buying an additional 160,300 shares during the last quarter. 683 Capital Management LLC raised its holdings in Pyxis Oncology by 69.9% in the 4th quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after acquiring an additional 366,910 shares during the period. Finally, J. Derek Lewis & Associates Inc. acquired a new stake in Pyxis Oncology during the fourth quarter worth approximately $61,000. 39.07% of the stock is owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc (NASDAQ: PYXS) is a clinical-stage biotechnology company developing therapies for cancer. The company focuses on treatments designed to address both tumor cells and the tumor microenvironment, with the goal of improving the effectiveness of the immune system and other anticancer mechanisms against solid tumors.

Its research and development programs include antibody-drug conjugates and immunotherapies. Pyxis Oncology’s lead program, PYX-201, is an antibody-drug conjugate designed to target the extradomain B form of fibronectin, a protein found in the tumor microenvironment, and deliver an anticancer payload to tumor tissue.